Assetmark Inc. acquired a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 611 shares of the company’s stock, valued at approximately $52,000.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Iron Triangle Partners LP acquired a new stake in shares of Axsome Therapeutics in the third quarter valued at approximately $22,671,000. Principal Financial Group Inc. increased its stake in shares of Axsome Therapeutics by 6,002.7% in the 4th quarter. Principal Financial Group Inc. now owns 207,065 shares of the company’s stock valued at $17,520,000 after buying an additional 203,672 shares during the period. FMR LLC raised its position in shares of Axsome Therapeutics by 20.6% during the third quarter. FMR LLC now owns 1,088,087 shares of the company’s stock worth $97,786,000 after acquiring an additional 185,951 shares during the last quarter. abrdn plc lifted its stake in shares of Axsome Therapeutics by 553.3% during the fourth quarter. abrdn plc now owns 72,179 shares of the company’s stock valued at $6,107,000 after acquiring an additional 61,131 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in Axsome Therapeutics by 47.5% in the third quarter. Franklin Resources Inc. now owns 160,534 shares of the company’s stock valued at $13,713,000 after acquiring an additional 51,696 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.
Axsome Therapeutics Stock Performance
Shares of AXSM opened at $121.91 on Friday. The firm has a fifty day simple moving average of $112.25 and a 200 day simple moving average of $98.88. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $139.13. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The stock has a market capitalization of $5.94 billion, a price-to-earnings ratio of -20.35 and a beta of 1.00.
Wall Street Analysts Forecast Growth
A number of analysts have commented on AXSM shares. Deutsche Bank Aktiengesellschaft began coverage on shares of Axsome Therapeutics in a report on Tuesday, February 11th. They set a “buy” rating and a $176.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $153.00 price objective on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. Truist Financial lifted their price objective on Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. William Blair reaffirmed an “outperform” rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. Finally, Leerink Partners boosted their target price on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, February 10th. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, Axsome Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $167.36.
Get Our Latest Analysis on Axsome Therapeutics
Insider Buying and Selling at Axsome Therapeutics
In other news, CFO Nick Pizzie sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 22.40% of the company’s stock.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Read More
- Five stocks we like better than Axsome Therapeutics
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Do ETFs Pay Dividends? What You Need to Know
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What is the S&P 500 and How It is Distinct from Other Indexes
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report).
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.